Christiane D Thienelt

Suggest Changes
Learn More
7082 Background: Advanced NSCLC patients with a PS ≥ 2 have a poor prognosis and often receive less aggressive or no chemotherapy (CT) due to poor tolerance. CALGB study 9730 compared median and(More)
7087 Background: Little clinical data are available in BAC, a slow growing but relentlessly progressive clinico-pathologically defined adenocarcinoma patient subset in NSCLC. A 14% partial response(More)
  • 1